CY1113378T1 - Καινοτομος χρηση των αντισωματων αντι il-1bhta - Google Patents

Καινοτομος χρηση των αντισωματων αντι il-1bhta

Info

Publication number
CY1113378T1
CY1113378T1 CY20121100867T CY121100867T CY1113378T1 CY 1113378 T1 CY1113378 T1 CY 1113378T1 CY 20121100867 T CY20121100867 T CY 20121100867T CY 121100867 T CY121100867 T CY 121100867T CY 1113378 T1 CY1113378 T1 CY 1113378T1
Authority
CY
Cyprus
Prior art keywords
compounds
rheumatoid arthritis
receptor
antibodies
disrupt
Prior art date
Application number
CY20121100867T
Other languages
English (en)
Inventor
Phil Lowe
Hermann Gram
Thomas Jung
Timothy Wright
Trevor Mundel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113378(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1113378T1 publication Critical patent/CY1113378T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Η παρούσα περιγραφή αναφέρεται στη χρήση ενώσεων που διακόπτουν τη σύνδεση του συνδέτη IL-1β με τον IL-1 υποδοχέα (στο παρόν αναφερόμενες ως «Ενώσεις IL-1 βήτα»), όπως είναι μικρές μοριακές ενώσεις που διακόπτουν την αλληλεπίδραση του συνδέτη IL-1β με τον υποδοχέα IL-1, αντισώματα έναντι της IL-1β ή αντισώματα έναντι των υποδοχέων IL-1, π.χ. μόρια που προσδένουν την IL-1 β που περιγράφηκαν στο παρόν, π.χ. ενώσεις που προσδένουν την IL-1β ή τους υποδοχείς της IL-1, και/ή RNA ενώσεις που ελαττώνουν είτε τους συνδέτες IL-1β ή τα επίπεδα των πρωτεϊνικών υποδοχέων της IL-1, για την αντιμετώπιση και/ή τη πρόληψη των αυτό-φλεγμονωδών συνδρόμων, π.χ. της νεανικής ρευματοειδούς αρθρίτιδας ή του συνδρόμου ρευματοειδούς αρθρίτιδας των ενηλίκων και σε μεθόδους αντιμετώπισης και/ή πρόληψης των αυτό-φλεγμονωδών συνδρόμων, π.χ. της νεανικής ρευματοειδούς αρθρίτιδας ή του συνδρόμου της ρευματοειδούς αρθρίτιδας των ενηλίκων, στα θηλαστικά, συγκεκριμένα στους ανθρώπους.
CY20121100867T 2005-10-26 2012-09-24 Καινοτομος χρηση των αντισωματων αντι il-1bhta CY1113378T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73043505P 2005-10-26 2005-10-26
US74212505P 2005-12-02 2005-12-02
EP06826560A EP1940465B1 (en) 2005-10-26 2006-10-24 Novel use of anti il-1beta antibodies

Publications (1)

Publication Number Publication Date
CY1113378T1 true CY1113378T1 (el) 2015-11-04

Family

ID=37806690

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20121100867T CY1113378T1 (el) 2005-10-26 2012-09-24 Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY2013046C CY2013046I1 (el) 2005-10-26 2013-12-13 Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY20181100301T CY1120018T1 (el) 2005-10-26 2018-03-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
CY2018018C CY2018018I2 (el) 2005-10-26 2018-06-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα

Family Applications After (3)

Application Number Title Priority Date Filing Date
CY2013046C CY2013046I1 (el) 2005-10-26 2013-12-13 Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY20181100301T CY1120018T1 (el) 2005-10-26 2018-03-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
CY2018018C CY2018018I2 (el) 2005-10-26 2018-06-12 Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα

Country Status (29)

Country Link
US (8) US8105587B2 (el)
EP (5) EP2848258B1 (el)
JP (4) JP2009513645A (el)
KR (3) KR101518064B1 (el)
CN (2) CN102861332A (el)
AU (1) AU2006306280B2 (el)
BR (1) BRPI0617830B8 (el)
CA (3) CA2898369C (el)
CY (4) CY1113378T1 (el)
DK (2) DK1940465T3 (el)
ES (3) ES2389110T3 (el)
HK (3) HK1121041A1 (el)
HU (2) HUE036973T2 (el)
IL (4) IL190545A (el)
JO (2) JO2826B1 (el)
LT (3) LT2848258T (el)
LU (2) LU92326I2 (el)
MA (1) MA29919B1 (el)
NO (2) NO345888B1 (el)
NZ (1) NZ567222A (el)
PH (2) PH12013501287B1 (el)
PL (2) PL1940465T3 (el)
PT (2) PT2848258T (el)
RU (2) RU2468817C2 (el)
SI (2) SI1940465T1 (el)
TN (1) TNSN08189A1 (el)
TR (1) TR201802449T4 (el)
TW (3) TWI537003B (el)
WO (1) WO2007050607A2 (el)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2848258T (lt) 2005-10-26 2018-02-26 Novartis Ag Šeiminės viduržemio jūros karštligės gydymas su anti-il-1 beta antikūnais
EP3406263A1 (en) * 2007-05-29 2018-11-28 Novartis AG New indications for anti-il-1beta therapy
AU2012203932B2 (en) * 2007-05-29 2014-04-24 Novartis Ag New indications for anti-IL-I-beta therapy
PT2293816E (pt) * 2008-06-06 2013-02-13 Xoma Technology Ltd Métodos para o tratamento da artrite reumatoide
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
CN102655880A (zh) * 2009-10-15 2012-09-05 雅培制药有限公司 Il-1结合蛋白
PE20130205A1 (es) * 2010-05-14 2013-03-24 Abbvie Inc Proteinas de union a il-1
US8853365B2 (en) * 2010-12-21 2014-10-07 Abbvie Inc. Dual variable domain immunnoglobulins and uses thereof
BR112013028808A2 (pt) 2011-05-10 2016-09-06 Nestec Sa métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada
EP3426775A1 (en) 2016-03-10 2019-01-16 Novartis AG Chemically modified messenger rna's
CA3064529C (en) 2017-05-31 2021-12-14 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in crohn's disease patients
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
EP3790576A1 (en) 2018-05-09 2021-03-17 Novartis Ag Use of canakinumab
KR20210107730A (ko) 2018-12-21 2021-09-01 노파르티스 아게 골수 형성이상 증후군의 치료 또는 예방에서의 il-1 베타 항체의 용도
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
WO2020128620A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
WO2023132698A1 (ko) * 2022-01-10 2023-07-13 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5350683A (en) * 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
AU1513495A (en) 1993-12-14 1995-07-03 University Of Pittsburgh Systemic gene treatment of connective tissue diseases
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP1153038A1 (en) 1999-02-10 2001-11-14 Interleukin Genetics, Inc. Therapeutics and diagnostics based on a il-1b mutation
DK1210320T3 (da) * 1999-07-16 2005-01-31 Leo Pharma As Aminobenzofenoner som inhibitorer for IL-1beta og TNF-alfa
ATE264863T1 (de) 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-epirapaloge
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP2329842A3 (en) * 2000-05-12 2011-07-27 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
KR20080014934A (ko) 2000-11-07 2008-02-14 노파르티스 아게 단백질 키나제 ｃ 억제제로서의 인돌릴말레이미드 유도체
JP2004536605A (ja) * 2001-07-26 2004-12-09 イーライ・リリー・アンド・カンパニー インターロイキン１β抗体
CA2456762A1 (en) * 2001-08-07 2003-02-20 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
WO2003049256A2 (en) 2001-12-01 2003-06-12 Iskra Wind Turbine Manufacturers Limited Ac synchronous generator incorporating a braking mechansim
KR200268109Y1 (ko) 2001-12-06 2002-03-15 김정훈 편평형 무정류자 진동모터
ES2485841T3 (es) 2002-02-01 2014-08-14 Ariad Pharmaceuticals, Inc Compuestos que contienen fósforo y usos de los mismos
CN1697647A (zh) 2002-02-01 2005-11-16 奥默罗斯公司 用于抑制疼痛,炎症和软骨退化的溶液及方法
WO2003068152A2 (en) * 2002-02-11 2003-08-21 Arkion Life Sciences Llc Purified cytokine inhibitory factor
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
JP2006514021A (ja) 2002-12-09 2006-04-27 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム Ｊａｎｕｓチロシンキナーゼ３（Ｊａｋ３）を選択的に阻害するための方法
WO2004067568A2 (en) 2003-01-24 2004-08-12 Applied Molecular Evolution, Inc Human il-1 beta antagonists
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
JP2007510931A (ja) 2003-11-10 2007-04-26 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｉｌ−１８をモニターするための方法
EP1704145B1 (en) 2004-01-12 2012-06-13 YM BioSciences Australia Pty Ltd Selective kinase inhibitors
ES2523147T3 (es) * 2004-02-26 2014-11-21 Baylor Research Institute Composiciones y métodos para el tratamiento sistémico de la artritis
US7531570B2 (en) * 2004-05-27 2009-05-12 Vertex Pharmaceuticals Incorporated Treatment of diseases using ICE inhibitors
AU2005249570B2 (en) * 2004-06-04 2011-06-16 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat autoinflammatory disease
EP1883427A4 (en) 2005-01-20 2010-04-21 Univ Rochester COMPOSITIONS AND METHODS FOR STUDYING AND TREATING INFLAMMATORY DISEASES AND DISORDERS
BRPI0609040B1 (pt) 2005-03-18 2018-07-31 Microbia, Inc. Fungo recombinante do gênero yarrowia, método de produção de um carotenóide e método de preparo de um aditivo alimentício ou ração contendo um carotenóide
KR101502920B1 (ko) 2005-06-21 2015-03-17 조마 (유에스) 엘엘씨 ＩＬ-１β 결합성 항체 및 그의 단편
LT2848258T (lt) 2005-10-26 2018-02-26 Novartis Ag Šeiminės viduržemio jūros karštligės gydymas su anti-il-1 beta antikūnais

Also Published As

Publication number Publication date
HK1121041A1 (en) 2009-04-17
TWI626056B (zh) 2018-06-11
NO345140B1 (no) 2020-10-12
US9649377B2 (en) 2017-05-16
CY1120018T1 (el) 2018-12-12
EP1940465A2 (en) 2008-07-09
RU2008120625A (ru) 2010-01-20
ES2944067T3 (es) 2023-06-19
PH12020500559A1 (en) 2021-06-14
TW201302220A (zh) 2013-01-16
BRPI0617830A2 (pt) 2011-08-09
US20210147533A1 (en) 2021-05-20
BRPI0617830B8 (pt) 2021-05-25
TWI388335B (zh) 2013-03-11
CA2898369A1 (en) 2007-05-03
EP3332807A2 (en) 2018-06-13
CA2963828A1 (en) 2007-05-03
LU92326I2 (fr) 2014-02-05
RU2468817C2 (ru) 2012-12-10
HUS1800025I1 (hu) 2018-07-30
KR101518064B1 (ko) 2015-05-06
CN102861332A (zh) 2013-01-09
US8409576B2 (en) 2013-04-02
LU92326I9 (el) 2019-01-16
JP2017206552A (ja) 2017-11-24
CN101291693A (zh) 2008-10-22
LTC1940465I2 (lt) 2017-12-11
NO345888B1 (no) 2021-09-27
ES2662420T3 (es) 2018-04-06
EP3332807A3 (en) 2018-06-20
PL1940465T3 (pl) 2013-01-31
US20150322148A1 (en) 2015-11-12
IL245387A0 (en) 2016-06-30
TNSN08189A1 (en) 2009-10-30
CA2626214C (en) 2016-06-21
AU2006306280A1 (en) 2007-05-03
CN101291693B (zh) 2012-10-03
DK2848258T3 (en) 2018-03-19
LUC00078I2 (fr) 2018-08-14
NZ567222A (en) 2011-07-29
EP1940465B1 (en) 2012-08-01
EP4218815A2 (en) 2023-08-02
JOP20140120B1 (ar) 2021-08-17
CY2013046I2 (el) 2015-11-04
IL190545A (en) 2016-09-29
JP6061747B2 (ja) 2017-01-18
AU2006306280B2 (en) 2010-06-17
CA2626214A1 (en) 2007-05-03
EP2848258B1 (en) 2017-12-13
TWI537003B (zh) 2016-06-11
JP2013166757A (ja) 2013-08-29
WO2007050607A3 (en) 2007-06-28
IL258983A (en) 2018-06-28
PL2848258T3 (pl) 2018-06-29
ES2389110T3 (es) 2012-10-23
JO2826B1 (en) 2014-09-15
MA29919B1 (fr) 2008-11-03
NO20082344L (no) 2008-07-22
KR20170038131A (ko) 2017-04-05
US20240083997A1 (en) 2024-03-14
PT2848258T (pt) 2018-03-20
BRPI0617830B1 (pt) 2020-10-20
CY2018018I1 (el) 2018-12-12
CA2898369C (en) 2017-06-20
US20120039910A1 (en) 2012-02-16
IL258983B (en) 2020-10-29
KR20080059598A (ko) 2008-06-30
NO20200810A1 (no) 2008-07-22
CY2013046I1 (el) 2015-11-04
KR20150013834A (ko) 2015-02-05
LT2848258T (lt) 2018-02-26
LTPA2018506I1 (lt) 2018-06-25
US20170218063A1 (en) 2017-08-03
HK1252316A1 (zh) 2019-05-24
IL190545A0 (en) 2008-11-03
TW200803898A (en) 2008-01-16
SI1940465T1 (sl) 2012-10-30
US8105587B2 (en) 2012-01-31
US20080286266A1 (en) 2008-11-20
PH12013501287A1 (en) 2016-02-01
EP4218815A3 (en) 2024-03-27
JP2016020377A (ja) 2016-02-04
EP2332577A1 (en) 2011-06-15
WO2007050607A2 (en) 2007-05-03
HK1204767A1 (en) 2015-12-04
JP2009513645A (ja) 2009-04-02
CY2018018I2 (el) 2018-12-12
JP6286403B2 (ja) 2018-02-28
RU2571563C2 (ru) 2015-12-20
EP3332807B1 (en) 2023-02-22
US20130171167A1 (en) 2013-07-04
TR201802449T4 (tr) 2018-03-21
LTC2848258I2 (lt) 2019-08-12
HUE036973T2 (hu) 2018-08-28
IL277406A (en) 2020-11-30
TW201617097A (zh) 2016-05-16
SI2848258T1 (en) 2018-03-30
US20180201674A1 (en) 2018-07-19
DK1940465T3 (da) 2012-10-22
IL245387B (en) 2019-09-26
EP2848258A1 (en) 2015-03-18
KR101749388B1 (ko) 2017-06-20
PT1940465E (pt) 2012-10-03
RU2012133522A (ru) 2014-02-20
PH12013501287B1 (en) 2016-02-01

Similar Documents

Publication Publication Date Title
CY1113378T1 (el) Καινοτομος χρηση των αντισωματων αντι il-1bhta
CY1123030T1 (el) Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων
CY1122674T1 (el) Αντι-c5α συνδετiκα μορια με υψηλου βαθμου δραστiκοτητα αποκλεισμου
DK1772465T3 (da) Syntetiske immunoglobulindomæner med modificerede bindingsegenskaber i områder af molekylet, der ikke er komplementaritetsbestemmende regioner
CY1122658T1 (el) Αντισωματα συνδεσης ανθρωπινου cgrp υποδοχεα
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
CY1117241T1 (el) Αντισωματα anti-igf
CY1116167T1 (el) Φαρμακευτικeς συνθεσεις κατευθυνομενες σε υποδοχεις erb-b1
DK1912674T3 (da) Bispecifikt enkeltkæde FV-antistofmolekyle og fremgangsmåder til anvendelse deraf
BRPI0606398A (pt) moléculas de criptoligação
CY1111796T1 (el) Ανοσοθεραπευτικο cd37 και συνδυασμος αυτου με διλειτουργικο χημειοθεραπευτικο
CY1113087T1 (el) Ανθρωπινα αντισωματα εναντιον δελτα-παρομοιου προσδεματος 4
MX2009012948A (es) Nuevas indicaciones para la terapia anti-il-1-beta.
WO2006117782A3 (en) Recombinant antibodies against cd55 and cd59 and uses thereof
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
CY1118918T1 (el) Παραγοντες εξαλειψης κυτταρων β, οπως αντισωματα enanti-cd20 ή θραυσματα αυτων για την αντιμετωπιση συνδρομου χρονιας κοπωσης
Fuchs et al. How Large are Cooperative Effects in Hydrogen Bonded Molecular Chains?
CY1117275T1 (el) Μεθοδοι θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος enanti-erbb-μεϊτανσινοειδους
CY1113928T1 (el) Αντισωματα αντι-μυοστατινης